Subgroup | n/N (%) |
---|---|
AML subtype | |
Therapy-related AML# | 7/10 (70) |
AML arising from prior MDS, MDS/MPN, or MPN (without prior therapy) | 4/5 (80) |
AML arising from prior MDS, MDS/MPN, or MPN (with prior HMA or chemotherapy) | 10/17 (59) |
AML-MRC* | 3/4 (75) |
Cytogenetics | |
Poor-risk cytogenetics | 11/21 (52) |
Non-poor-risk cytogenetics | 10/11 (91) |
ELN 2017 cytomolecular risk | |
Intermediate | 5/5 (100) |
Adverse | 16/27 (59) |
TP53-mutated | 7/11 (64) |
MECOM-rearranged | 2/4 (50) |